Lymph Node Pathologic Grading Strategy

Lymph Node Pathologic Grading Strategy: Under the Backdrop of the IASLC Grading System for Invasive Lung Adenocarcinoma - a Retrospective Cohort Study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06745830

Enrollment

2998

Registered

2024-12-20

Start date

2024-04-10

Completion date

2025-04-20

Last updated

2024-12-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Adenocarcinoma

Brief summary

The percentage of high-grade patterns in metastatic LNs (mLNs) that can predict poor outcomes has yet to be determined. Additionally, the potential implications of other histologic patterns in metastatic lymph nodes on patient outcomes warrant further investigation. We conducted a retrospective cohort study to investigate the prognostic value of pathologic pattern in metastatic lymph nodes.

Interventions

OTHERNo intervention

No intervention

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

From January 2011 to September 2021, we consecutively collected patients with invasive LUAD who underwent surgical resection at the Department of Thoracic Surgery, Fudan University Shanghai Cancer Center.

Exclusion criteria

1. adenocarcinoma in situ, minimally invasive adenocarcinoma, invasive mucinous adenocarcinoma, and other variants of adenocarcinoma; 2. incomplete common driver mutation data; 3. unavailable pathologic slides.

Design outcomes

Primary

Measure	Time frame
5-year RFS	5 years

Secondary

Measure	Time frame
5-year OS	5 years

Countries

China

Contacts

Primary ContactZhu

20301050177@fudan.edu.cn13301970795

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026